Top > Search of International Patents > PEPTIDE-BOUND LIPOSOME, CYTOTOXIC T LYMPHOCYTE ACTIVATOR, AND ANTITUMOR VACCINE

PEPTIDE-BOUND LIPOSOME, CYTOTOXIC T LYMPHOCYTE ACTIVATOR, AND ANTITUMOR VACCINE

Foreign code F160008807
File No. (S2014-1594-N0)
Posted date Aug 4, 2016
Country WIPO
International application number 2015JP076214
International publication number WO 2016047509
Date of international filing Sep 16, 2015
Date of international publication Mar 31, 2016
Priority data
  • P2014-196454 (Sep 26, 2014) JP
Title PEPTIDE-BOUND LIPOSOME, CYTOTOXIC T LYMPHOCYTE ACTIVATOR, AND ANTITUMOR VACCINE
Abstract A peptide-bound liposome wherein a peptide comprising the amino acid sequence represented by SEQ ID NO:14 is bound to the surface of a liposome.
Outline of related art and contending technology BACKGROUND ART
In recent years, T lymphocytes are cytotoxic to a tumor antigen (hereinafter, sometimes referred to as' CTL ') inducing a reaction, the activated CTL is expected to be in the tumor cells may be eliminated immune therapy are under research and development has been actively carried out. The immunotherapy includes, tumor antigen peptides of the vaccine-induced CTL developed with the center.
So far, Telomere Reverse Transcriptase (hereinafter, sometimes referred to as' TERT ') a tumor antigen peptide is a target antigen has been proposed (for example, see Patent Document 1 and 2). The TERT is, various types of clinical tumor expression is observed in a time sharing about 9 pan-tumor antigen. Therefore, cause a strong immune response against the antigen derived from TERT vaccine, which is highly versatile and universal anti-tumor vaccine that can be expected.
In general, search for candidate vaccine antigen epitope, the amino acid sequence of antigenic proteins may be analyzed by a computer algorithm, the expectation that high affinity HLA material should be selected in many cases (for example, see non-patent document 1). The TERT in using peptide vaccine-derived antigens, peptide antigens currently in clinical trials is 540-548, the native sequence of the TERT in the prediction for the highest affinity HLA-A2 sequence (for example, see non-patent document 2).
However, so far fully satisfactory in the anti-tumor vaccine is not provided. This is, detected from the peripheral blood of patients with tumor tumor antigen-specific cytotoxic T lymphocytes, react to antigen stimulation entereds be considered that the reason. This is caused, neoplastic growth in the course of, and has a high affinity HLA, to the host immune system can be easily identified from tumor cells presented CTL epitope, it is considered that immune tolerance is induced. In addition, the tumor antigen peptide, MHC class I receptor also coupled for, inappropriate co-stimulation in the form lacking the antigen-presenting cells and thus T, administered antigen specific immune tolerance can cause also contemplated.
Therefore, the self antigen is derived from the protein at high affinity epitope TERT, neoplastic growth T lymphocytes from the tumor cells to the antigen in the course presented, as a result, a problem that the immune tolerance is induced may be considered. Antigen-specific immune tolerance is induced in the case, antigen-specific T lymphocytes non-responsive state and to the activation stimulus, sufficient anti-tumor effect and cytotoxic T lymphocytes induced by anti-tumor vaccine is expected to be difficult.
On the other hand, so far, the surface of the liposomes composed of unsaturated fatty acids may be coupled with an antigenic peptide, a professional antigen presenting cell (hereinafter, sometimes referred to as' pAPC ') incorporated in the specific, MHC class I cross-presentation to the, co-stimulation with antigen presented in a form suitable for known (for example, see non-patent document 3).
However, without inducing immune tolerance, which can cause a cellular immune response, anti-tumor vaccine has not been developed yet, it is strongly demanded to provide a rapid.
Scope of claims (In Japanese)[請求項1]
配列番号:14で表されるアミノ酸配列からなるペプチドが、リポソームの表面に結合していることを特徴とするペプチド結合リポソーム。
[請求項2]
リポソームが、不飽和結合を1個有する炭素数14~24のアシル基、及び不飽和結合を1個有する炭素数14~24の炭化水素基のいずれかを有するリン脂質と、リポソームの安定化剤とを含む請求項1に記載のペプチド結合リポソーム。
[請求項3]
リン脂質が、不飽和結合を1個有する炭素数14~24のアシル基を有するリン脂質である請求項2に記載のペプチド結合リポソーム。
[請求項4]
アシル基が、オレイル基である請求項2から3のいずれかに記載のペプチド結合リポソーム。
[請求項5]
リン脂質が、ジアシルホスファチジルセリン、ジアシルホスファチジルグリセロール、ジアシルホスファチジン酸、ジアシルホスファチジルコリン、ジアシルホスファチジルエタノールアミン、サクシンイミジル-ジアシルホスファチジルエタノールアミン、及びマレイミド-ジアシルホスファチジルエタノールアミンから選ばれる少なくとも1つである請求項2から4のいずれかに記載のペプチド結合リポソーム。
[請求項6]
リポソームの安定化剤が、コレステロールである請求項2から5のいずれかに記載のペプチド結合リポソーム。
[請求項7]
ペプチドが、不飽和結合を1個有する炭素数14~24のアシル基、及び不飽和結合を1個有する炭素数14~24の炭化水素基のいずれかを有するリン脂質に結合している請求項2から6のいずれかに記載のペプチド結合リポソーム。
[請求項8]
請求項1から7のいずれかに記載のペプチド結合リポソームを含有することを特徴とする細胞傷害性Tリンパ球活性化剤。
[請求項9]
更に、アジュバントを含有する請求項8に記載の細胞傷害性Tリンパ球活性化剤。
[請求項10]
請求項1から7のいずれかに記載のペプチド結合リポソームを含有することを特徴とする抗腫瘍ワクチン。
[請求項11]
更に、アジュバントを含有する請求項10に記載の抗腫瘍ワクチン。
  • Applicant
  • ※All designated countries except for US in the data before July 2012
  • SAITAMA MEDICAL UNIVERSITY
  • Inventor
  • HORIUCHI, Yutaka
  • AKATSUKA, Toshitaka
  • UCHIDA, Tetsuya
IPC(International Patent Classification)
Specified countries National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG

PAGE TOP

close
close
close
close
close
close